When will generic ivabradine be available?

What's the Status of Generic Ivabridine Availability?

Ivabradine, sold under the brand name Corlanor, is a prescription medication used to treat atrial fibrillation and high blood pressure. According to a patent search on DrugPatentWatch.com [1], Novartis, the original manufacturer, lost patent protection for ivabradine in many countries in 2019. The patent protection in the United States expired in 2018.

Why Haven't We Seen Generic Ivabridine Yet?

Although the patent has expired, generic versions of ivabradine are expected to take some time to enter the market. Generic manufacturers need to submit and receive approval from regulatory agencies like the FDA before launching their products. This process typically involves clinical trials and quality assessments to ensure that the generic version is bioequivalent to the brand-name version.

When Can We Expect Generic Ivabradine to be Available?

As per a report from a pharmaceutical market research company, the first generic ivabradine is expected to be launched in 2025 or 2026. However, this date may change based on various factors, such as regulatory hurdles, manufacturing capacity, and competitive pressures.

Who Will Launch the First Generic Ivabradine?

The first generic ivabradine is expected to be launched by a company called Mylan Pharmaceuticals (now part of Viatris). Other companies may follow suit once the market is established.

Sources:

[1] DrugPatentWatch.com. Patent Expiration Dates for Ivabradine.